Formation of keto-type ceramides in palmoplantar keratoderma based on biallelic KDSR mutations in patients.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
31 03 2022
Historique:
received: 10 03 2021
revised: 14 10 2021
accepted: 18 10 2021
pubmed: 24 10 2021
medline: 9 4 2022
entrez: 23 10 2021
Statut: ppublish

Résumé

Functional skin barrier requires sphingolipid homeostasis; 3-ketodihydrosphingosine reductase or KDSR is a key enzyme of sphingolipid anabolism catalyzing the reduction of 3-ketodihydrosphingosine to sphinganine. Biallelic mutations in the KDSR gene may cause erythrokeratoderma variabilis et progressive-4, later specified as PERIOPTER syndrome, emphasizing a characteristic periorifical and ptychotropic erythrokeratoderma. We report another patient with compound heterozygous mutations in KDSR, born with generalized harlequin ichthyosis, which progressed into palmoplantar keratoderma. To determine whether patient-associated KDSR mutations lead to KDSR substrate accumulation and/or unrecognized sphingolipid downstream products in stratum corneum (SC), we analyzed lipids of this and previously published patients with non-identical biallelic mutations in KDSR. In SC of both patients, we identified 'hitherto' unobserved skin ceramides with an unusual keto-type sphingoid base in lesional and non-lesional areas, which accounted for up to 10% of the measured ceramide species. Furthermore, an overall shorter mean chain length of free and bound sphingoid bases was observed-shorter mean chain length of free sphingoid bases was also observed in lesional psoriasis vulgaris SC, but not generally in lesional atopic dermatitis SC. Formation of keto-type ceramides is probably due to a bottle neck in metabolic flux through KDSR and a bypass by ceramide synthases, which highlights the importance of tight intermediate regulation during sphingolipid anabolism and reveals substrate deprivation as potential therapy.

Identifiants

pubmed: 34686882
pii: 6408935
doi: 10.1093/hmg/ddab309
doi:

Substances chimiques

Ceramides 0
Sphingolipids 0
Oxidoreductases EC 1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1105-1114

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Robert Pilz (R)

Lipid Pathobiochemistry Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Lukáš Opálka (L)

Lipid Pathobiochemistry Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Skin Barrier Research Group, Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic.

Adam Majcher (A)

Lipid Pathobiochemistry Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Skin Barrier Research Group, Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic.

Elisabeth Grimm (E)

Lipid Pathobiochemistry Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Lionel Van Maldergem (L)

Centre de Génétique Humaine, Université de Franche-Comté, 25000 Besançon, France.
Clinical Investigation Center 1431, National Institute of Health and Medical Research (INSERM), University Hospital, 25000 Besançon, France.

Silvia Mihalceanu (S)

Department of Dermatology, Medical Faculty of the University of Heidelberg, 69120 Heidelberg, Germany.

Knut Schäkel (K)

Department of Dermatology, Medical Faculty of the University of Heidelberg, 69120 Heidelberg, Germany.

Alexander Enk (A)

Department of Dermatology, Medical Faculty of the University of Heidelberg, 69120 Heidelberg, Germany.

François Aubin (F)

Service de Dermatologie et INSERM 1098 RIGHT, CHU et UFR Santé, 25000 Besançon, France.

Anne-Claire Bursztejn (AC)

Department of Dermatology, University Hospital Nancy, 54000 Nancy, France.

Elise Brischoux-Boucher (E)

Centre de Génétique Humaine, Université de Franche-Comté, 25000 Besançon, France.

Judith Fischer (J)

Institute of Human Genetics, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany.

Roger Sandhoff (R)

Lipid Pathobiochemistry Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH